Aripiprazole and Tourette Syndrome [4];Aripiprazol e Síndrome de Tourette

Revista Brasileira de Psiquiatria

Volumn 26, Issue 3, 2004, Pages 213-

  Hounie, Ana ^a   De Mathis, Alice ^a   Santos Sampaio, Aline ^a   Tomanik Mercadante, Marcos ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BOTULINUM TOXIN; CLONAZEPAM; CLONIDINE; HALOPERIDOL; NEUROLEPTIC AGENT; NICOTINE; OLANZAPINE; PERGOLIDE; PIMOZIDE; QUETIAPINE; RESERPINE; RISPERIDONE; SERTRALINE; SULPIRIDE; TRIFLUOPERAZINE; ZIPRASIDONE;

ADULT; AGORAPHOBIA; BRAZIL; CASE REPORT; CLINICAL FEATURE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; GILLES DE LA TOURETTE SYNDROME; HUMAN; LETTER; MAJOR DEPRESSION; MALE; OBSESSIVE COMPULSIVE DISORDER; PANIC; SYMPTOM; TREATMENT FAILURE;

EID: 4644301603     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-44462004000300015     Document Type: Letter

References (5)

1. Sandor P. Pharmacological management of tics in patients with TS. Journal of Psychossomatoc Research. 2003;55:41-8.
2. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302(1):381-9.
3. Alexander GE, De Long MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci. 1986;9:357-81.
4. Singer HS. Neurobiology of Tourette Syndrome. Neurol Clin. 1997;15:357-79.
5. Lawer CP, Prioleau C, Lewis MM, et al. Intercations of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacol. 1999;20(6):612-27.